Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report

Area of Science:

• Pharmacovigilance
• Regulatory Science
• Drug Safety

Background:

• The 2012 International Conference on Harmonisation (ICH) E2C (R1) guideline revision introduced expanded scope for Periodic Safety Update Reports (PSURs).
• Key changes included dedicated sections for benefit assessment and integrated benefit-risk (B-R) analysis, leading to the new Periodic Benefit-Risk Evaluation Report (PBRER) title.
• Recent development of structured frameworks by industry and regulatory bodies aims to streamline B-R analysis for pharmaceuticals.

Purpose of the Study:

• To provide recommendations for integrating structured B-R assessment elements into the PBRER.
• To offer practical strategies for implementing ICH guidelines concerning the B-R analysis section of the PBRER.

Main Methods:

• Review and synthesis of ICH E2C (R1) guideline requirements.
• Analysis of structured B-R assessment frameworks.
• Development of practical implementation suggestions.

Main Results:

• Key components of a PBRER B-R assessment: decision context, key benefits/risks, evidence strengths/limitations/uncertainties, risk management, and overall B-R conclusions.
• Structured B-R assessment provides a systematic approach to evaluating a medicine's profile.
• Practical approaches facilitate the implementation of ICH guidelines for PBRER B-R analysis.

Conclusions:

• A structured, systematic approach to defining a medicine's benefit-risk profile is crucial for PBRER compliance.
• Effective implementation of B-R assessment enhances the quality and consistency of PBRERs.
• Adherence to these structured methods supports regulatory objectives for drug safety evaluation.